Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 7/20 | 0.55 |
| ▸ | WNT3A | P56704 | 7/20 | 0.55 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1403662 | 0.90 | FABP4 (0.56) | FABP4RAB9ANPC1POLBAKR1B1 | |
| SCHEMBL28840819 | 0.88 | AKR1B1 (0.47) | CTNNB1WNT3ARAB9APOLBAKR1B1 | |
| SCHEMBL5792636 | 0.86 | CTNNB1 (0.50) | CTNNB1WNT3ARAB9ANPC1POLB | |
| Formic Acid SCHEMBL28322635 | 0.85 | RAB9A (0.54) | FABP4RAB9ANPC1POLBAKR1B1 | |
| SCHEMBL8938407 | 0.85 | AKR1B1 (0.43) | CTNNB1WNT3AFABP4RAB9ANPC1 | |
| SCHEMBL11243863 | 0.82 | CTNNB1 (0.46) | CTNNB1WNT3AFABP4RAB9ANPC1 | |
| SCHEMBL30730257 | 0.82 | CTNNB1 (0.47) | CTNNB1WNT3ARAB9ANPC1POLB | |
| SCHEMBL31409465 | 0.82 | ALDH1A1 (0.57) | RAB9ANPC1AKR1B1ALDH1A1HPGD | |
| SCHEMBL24826094 | 0.81 | CTNNB1 (0.52) | CTNNB1WNT3AFABP4RAB9ANPC1 | |
| SCHEMBL1344385 | 0.81 | AKR1B1 (0.44) | CTNNB1WNT3AFABP4RAB9AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116601150-A | Fused bicyclic RAF inhibitors and methods of use thereof | 爵士制药爱尔兰有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-114907389-A | Boronic acid derivatives | 首药控股(北京)股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-2970285-B1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20190008866-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2019-01-10 | — | — | US | disclosed |
| EP-3089970-B1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-10085985-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20160331749-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-11-17 | — | — | US | disclosed |
| EP-3089970-A1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | AbbVie Inc. (US) | 2016-11-09 | — | — | EP | disclosed |
| US-9428514-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC (US) | 2016-08-18 | — | — | US | disclosed |
| WO-2015089075-A1 | DIHYDROPYRIDINONE AND DIHYDROPYRIDAZINONE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20150158873-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | disclosed |
| US-8980879-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2014165143-A1 | DIHYDRO-PYRROLOPYRIDINONE BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164780-A1 | FUSED TETRACYCLIC BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
| US-5288749-A | Treating central nervous system or cardiovascular disorders | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| WO-1993012754-A2 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150884-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CTNNB1 3620/4885WNT3A 2613/4885FABP4 3150/4885 |
| US-10085985-B2 | Bromodomain inhibitors | BRD4, BRD3, BRD1 | CTNNB1 3801/4885WNT3A 2917/4885FABP4 3091/4885 |
| US-20160237084-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | DPYD, QDPR, DHFR | CTNNB1 3473/4885WNT3A 4270/4885FABP4 4543/4885 |
| US-20190008866-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CTNNB1 3801/4885WNT3A 2917/4885FABP4 3091/4885 |
| US-20160331749-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CTNNB1 3801/4885WNT3A 2917/4885FABP4 3091/4885 |
| US-20140256710-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CTNNB1 3620/4885WNT3A 2613/4885FABP4 3150/4885 |
| US-20140275026-A1 | DIHYDRO-PYRROLOPYRIDINONE INHIBITORS | DPYD, QDPR, DHFR | CTNNB1 3473/4885WNT3A 4270/4885FABP4 4543/4885 |
| US-20150158873-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | CTNNB1 3801/4885WNT3A 2917/4885FABP4 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.